Summary
Pramodini Medicare is launching a ₹69 crore book-built SME IPO, with bidding from 12–14 August 2026 and listing proposed on the NSE SME.
The company offers technology-driven diagnostic services through radiology, pathology, nuclear medicine, and teleradiology across a multi-state network.
The IPO is backed by improving financials, but investors should weigh its pricing constraints, operational risks, and neutral GMP before investing.
Pramodini Medicare is launching a book-built IPO of 58,51,200 shares, amounting to ₹69 crore. It comprises both a fresh issue valued at ₹63 crore and an offer for sale (OFS) of ₹6 crore.
Bidding for the IPO starts on 12 August 2026. Investors can place their applications until the bidding window closes on 14 August 2026. The share allotment is likely to be finalised on 17 August 2026. The shares are expected to make their NSE SME debut on 19 August 2026.
The price band for the IPO is ₹110–₹118 per share. Applications can be made in lots of 1,200 shares. Retail investors must apply for a minimum of two lots (2,400 shares), while HNI investors need to apply for at least three lots (3,600 shares). At the upper price band, the minimum investment works out to ₹2,83,200 for retail investors and ₹4,24,800 for HNIs.
Pramodini Medicare IPO Key Details
The table below highlights the key details of the Pramodini Medicare IPO:
| Bidding Opens | 12 August 2026 |
| Bidding Closes | 14 August 2026 |
| Face Value | ₹10 per share |
| Issue Type | Bookbuilding |
| Price Band | ₹110 to ₹118 |
| Issue Price | |
| Listing at | NSE SME |
| Lot Size | 1,200 Shares |
| Offer for Sale (OFS) | 5,00,400 shares (₹6 crore) |
| Reserved For Market Maker | 3,36,000 shares (₹4 crore) |
| Fresh Issue | 50,14,800 shares (₹59 crore) |
| Total Issue | 58,51,200 shares (₹69 crore) |
| Minimum Investment | ₹2,83,200 |
Pramodini Medicare IPO Timeline
Below is an overview of the Pramodini Medicare IPO timeline:
| Bidding Opens | 12 August 2026 |
| Bidding Closes | 14 August 2026 |
| Allotment Planned For | 17 August 2026 |
| Refunds Start On | 18 August 2026 |
| Share Credit to Demat | 18 August 2026 |
| Listing Scheduled | 19 August 2026 |
| Cut-off for UPI mandate | 5:00 PM on 14 August 2026 |
Pramodini Medicare Key Performance Indicators (KPIs)
The KPIs of Pramodini Medicare are as follows:
| KPIs | FY 2026 | FY 2025 | FY 2024 |
| ROE (%) | 39.08 | 36.44 | 32.76 |
| ROCE (%) | 34.66 | 36.48 | 31.90 |
| Debt-Equity (times) | 0.34 | 0.30 | 0.48 |
| RoNW (%) | 32.69 | 30.83 | 28.00 |
| PAT Margin (%) | 27.90 | 28.84 | 19.67 |
| EBITDA Margin (%) | 49.61 | 54.83 | 44.10 |
| Price Book Value | 3.71 |
Pramodini Medicare Financials
The following table presents Pramodini Medicare’s financial figures:
| Period | FY 2026 | FY 2025 | FY 2024 |
| Total Assets | 9,361.52 | 5,644.65 | 4,878.00 |
| Revenue | 6,337.85 | 3,854.63 | 3,579.40 |
| Profit After Tax | 1,737.73 | 1,113.99 | 713.85 |
(Amount in ₹ lakh)
Pramodini Medicare IPO Subscription Status
The Pramodini Medicare IPO has not yet opened for subscription, so live subscription figures are currently unavailable.
The bidding data will be updated once the subscription window begins.
Investors can place their bids between 10:00 AM and 5:00 PM on each day of the subscription period.
Pramodini Medicare IPO Grey Market Premium (GMP Today)
As of 6 August 2026, the Pramodini Medicare IPO is trading at a GMP of ₹0. If this trend continues, the shares are expected to list at ₹118, implying no estimated listing gains. The current grey market sentiment remains neutral.
| Date | GMP | Est. Debut Price (Cap Price + GMP) | Est. Listing Profit | Trend | Last Updated |
| 06-08-2026 | ₹0 | ₹118 (0.00%) | ₹0 | Neutral | 6 Aug 2026 7:56 |
| 05-08-2026 | ₹0 | ₹118 (0.00%) | ₹0 | Decreasing | 5 Aug 2026 23:32 |
| 04-08-2026 | ₹0 | 3 Aug 2026 19:10 |
Note: GMP is an informal market indicator and should not be relied upon as a guarantee of listing gains
Pramodini Medicare IPO Reservation
The share reservation for different investor categories is detailed below:
| Investor Category | Reservation |
| Market Maker | 3,36,000 |
| QIB | 25,32,000 |
| Anchor Investor | 13,60,800 |
| QIB (Ex. Anchor) | 11,71,200 |
| NIIs | 9,60,000 |
| Retail Investors | 20,23,200 |
| Total Shares | 58,51,200 |
Pramodini Medicare IPO Lot Size
The lot sizes and minimum investment requirements are as follows:
| Application Type | Lots | Shares | Amount |
| Individual Investor – Minimum | 2 | 2,400 | ₹2,83,200 |
| Individual Investor – Maximum | 2 | 2,400 | ₹2,83,200 |
| S-HNI Minimum | 3 | 3,600 | ₹4,24,800 |
| S-HNI Maximum | 7 | 8,400 | ₹9,91,200 |
| B-HNI Minimum | 8 | 9,600 | ₹11,32,800 |
Pramodini Medicare IPO Anchor Investors
The table below provides the anchor investor details for this IPO:
| Particulars | Details |
| Bidding Opens | 11 August 2026 |
| Shares Offered | 13,60,800 |
| Portion Size | Up to 60% of the QIB portion |
| 30-Day Lock-in for 50% Shares | 16 September 2026 |
| 90-Day Lock-in for Remaining Shares | 15 November 2026 |
Pramodini Medicare IPO Prospectus
To learn more about the Pramodini Medicare IPO, check the resources below:
About Pramodini Medicare
Incorporation: 12 September 2000
Managing Director: Dr Chalasani Kuldeep Kumar
Pramodini Medicare is a diagnostic healthcare company offering radiology, nuclear medicine, teleradiology, and pathology services. It covers MRI, CT scans, X-rays, ultrasound, mammography, PET-CT and SPECT for imaging, along with lab testing in microbiology, immunology, haematology and biochemistry.
The business runs on four models, public-private partnerships, private hospital partnerships, PSU partnerships, and standalone diagnostic centres. Alongside this, Pramodini Medicare continues to invest in advanced diagnostic equipment and grow its network, strengthening its position in India’s fast-expanding diagnostics sector.
| Issue Registrar | Purva Sharegistry (India) Pvt.Ltd. |
| Lead Manager | Smart Horizon Capital Advisors Pvt.Ltd. |
Pramodini Medicare IPO Objectives
The net proceeds from the IPO will be utilised for the following purposes:
| Particulars | Amount (in ₹ lakh) |
| Capex for medical equipment at existing and proposed diagnostic centres | 4,514.85 |
| General corporate purposes |
Strengths of Pramodini Medicare
- Multi-State Presence: The company operates 16 diagnostic centres across 14 cities in seven states, expanding its footprint through a steady, partnership-led growth strategy.
- Strong Technology Infrastructure: The company uses advanced diagnostic equipment and modern IT systems to deliver accurate results, faster reporting, and efficient operations across its centres.
- Experienced Leadership: The business is guided by healthcare professionals and promoters with over two decades of experience in the field, backed by a seasoned management team.
- Diversified Customer Base: The company caters to a variety of customers, from government institutions and hospitals to individual patients, which keeps its revenue mix balanced.
Risks of Pramodini Medicare
- Geographical Concentration: Andhra Pradesh accounted for 61.90% of FY2026 revenue, leaving the business exposed to regional slowdowns, local disruptions, or unfavourable developments in that market.
- Pricing Constraints: The prices of many services are often locked in under MOUs. The company has limited room to offset rising costs or safeguard its operating margins.
- Quality and Diagnostic Errors: Mistakes in testing, reporting, sample handling, or diagnosis could harm patients and lead to legal claims, financial losses, and damage to the company’s reputation.
- Bank Guarantee Obligations: Certain PSU partnerships require the company to furnish bank guarantees. This adds to working capital requirements and impacts the cash flow.
Pramodini Medicare IPO Review
Pramodini Medicare has built a diversified diagnostics business backed by modern technology, an experienced management team, and a wide customer base. Its improving financial performance and healthy profitability point to steady execution, along with the benefits of expanding its diagnostic network.
However, long-term MOUs leave little room for pricing flexibility and the business carries operational risks associated with diagnostic services. With the GMP pointing to muted market sentiment, the IPO seems better suited to investors with a longer investment horizon rather than those chasing listing gains.
Overall, the IPO offers a fairly balanced risk-reward profile, so it is worth weighing the fundamentals and valuation carefully before investing.
Other Recent IPO List
Keep track of upcoming IPOs in India for 2026:
| Anawil Wire and Engineering IPO | Aegeus Technologies IPO |
| LAPL Automotive IPO | Optimystix Entertainment India IPO |
| Ardee Industries IPO | Technocraft Ventures IPO |
| Fusion Klassroom Edutech IPO | G.V Electricals IPO |
Pramodini Medicare IPO FAQs
The Pramodini Medicare IPO is a ₹69 crore book-built SME issue comprising a fresh issue and an offer for sale. The shares will be listed on the NSE SME platform.
You can apply for the Pramodini Medicare IPO through your stockbroker or an online trading platform using the ASBA facility or a UPI-enabled application. Make sure to submit your application before the subscription window closes.
The company has reported strong financial growth and healthy profitability, supported by an expanding diagnostics network. However, investors should also consider its concentrated revenue, operational challenges, and the current neutral GMP before investing.
The current GMP is ₹0, indicating no expected listing gains. However, GMP is unofficial and may not reflect the actual listing performance.
The IPO will open for subscription on 12 August 2026 and close on 14 August 2026.
The lot size is 1,200 shares. Retail investors must apply for a minimum of 2,400 shares (2 lots), amounting to ₹2,83,200.
The IPO allotment is expected to be finalised on 17 August 2026.
The shares are scheduled to be listed on the NSE SME on 19 August 2026.
